Unlocking New Avenues in KRAS-Driven Cancer Research Beyond G12C

The KRAS G12C mutation obstructs the binding of GAP to KRAS, preventing GTP hydrolysis and keeping G12C-mutant KRAS continuously active. This sustained activation triggers the MAPK and PI3K signaling pathways, fueling the formation of tumors. Drugs like sotorasib and adagrasib directly target KRAS G12C by forming a bond with cysteine 12 in the KRAS-G12C protein’s switch-II pocket. This action locks KRAS in an inactive state, halting cell proliferation. While inhibiting KRAS G12C proves effective against certain lung cancers, it doesn’t impact PI3K signaling. This suggests that alternative pathways unrelated to KRAS-G12C might activate PI3K, contributing to resistance against G12C inhibitors and prompting the development of new therapies. G12C stands as the primary focus in KRAS targeting, yet newer studies reveal emerging targets like G12D, although their treatment paths are less established. Some companies are exploring PAN-KRAS inhibition as a novel treatment method. For instance, Onvansertib, currently in a Phase II trial for metastatic colorectal cancer treatment, aims to address all KRAS mutations by activating PLK1, which triggers RAS downstream pathways.

Epidemiological Insights into Geographic Distribution of KRAS Mutations

The identification of KRAS mutations dates back to the 1980s, and it has since been recognized as a prevalent mutation in various cancers such as lung cancer, colorectal cancer, and pancreatic cancer. Among these, the G12C variant is the most widespread in non-small cell lung cancer (NSCLC) across the United States, Europe, and Japan, occurring in approximately 35–40% of KRAS-mutated NSCLC patients in 2025, as per DelveInsight analysis. Immunotherapy stands as the standard of care for individuals with KRAS-mutant NSCLC, especially those with G12C variations, as there are currently no authorized treatments specifically targeting this variant.

In colorectal cancers, around 40% exhibit KRAS mutations, with G12D being the predominant variant found in about 25–35% of individuals with KRAS mutations. Despite G12D being the most common variant, the majority of KRAS therapies for colorectal cancer focus on G12C, despite its lower prevalence in this cancer type. Ongoing developments include limited treatments for G12D and PAN-KRAS variants.

Pancreatic cancer, where KRAS mutations are present in 60–90% of patients, sees G12D as the most frequent KRAS variant, occurring in approximately 40–50% of KRAS-mutated patients. However, the development of effective “systemic” and “biomarker-specific” therapies for pancreatic cancer patients remains a substantial unmet need. Recognizing this, several key players in the pharmaceutical and biotech industries are increasingly exploring the potential of targeting KRAS mutations in pancreatic cancer, seeing this relatively unexplored segment as a promising market opportunity for cancer treatment.

The Therapeutic Landscape of KRAS Inhibitors: Progress and Promise

KRAS-targeted therapy has rapidly evolved from a long-standing scientific challenge into one of oncology’s most competitive therapeutic areas. A major breakthrough came with the approval of Amgen’s sotorasib (LUMAKRAS), the first approved targeted treatment for NSCLC patients with the KRAS G12C mutation in 2021, followed by Bristol Myers Squibb’s adagrasib (KRAZATI) in 2022. Both therapies received accelerated approvals based on their ability to deliver clinically meaningful responses in KRAS G12C-mutated NSCLC, establishing KRAS as a druggable oncogenic target after decades of failed attempts. While both therapies have demonstrated comparable efficacy, they differ in their clinical profiles. Adagrasib demonstrates the ability to penetrate the central nervous system, making it a valuable treatment option for patients with brain metastases, which develop in approximately 40% of patients with KRAS G12C-mutated NSCLC during the course of their disease. In contrast, sotorasib is generally associated with a more favorable safety profile and longer duration of response. However, adagrasib has been associated with QTc interval prolongation and gastrointestinal toxicities, necessitating careful clinical monitoring during treatment.

In the United States, Mirati’s drug adagrasib is priced at USD 19,750 for a 30-day supply, whereas sotorasib has a lower list price of USD 17,900 per month. Sotorasib, with an estimated list price of GBP 6,907 for a 30-day supply of 240 tablets (each containing 120 mg, excluding VAT and business submission), has a commercial arrangement in place (including a managed access agreement and a commercial access agreement). Adagrasib has not yet received licensing in Europe. Sotorasib 120 mg tablets are priced at approximately JPY 4,204 per tablet. Comparatively, current pricing indicates that in Japan and the UK, the prices are approximately 60% and 50% lower than those in the US. As competition intensifies, future pricing and reimbursement strategies are expected to evolve alongside the arrival of newer KRAS inhibitors. 

Expanding Opportunities in KRAS-mutated Colorectal Cancer (CRC)

Over 40% of individuals with metastatic CRC exhibit a KRAS mutation, rendering them intrinsically resistant to anti-EGFR monoclonal antibody monotherapy and representing a major unmet need in precision oncology. While KRAS G12C accounts for only approximately 3–4% of mCRC cases, it has become the first KRAS subtype to benefit from targeted therapies. Amgen’s sotorasib (LUMAKRAS), in combination with panitumumab, became the first KRAS G12C-targeted regimen approved for previously treated mCRC based on the Phase III CodeBreaK 300 study, establishing a new treatment option for this genetically defined patient population. In contrast, Bristol Myers Squibb’s adagrasib (KRAZATI) encountered a significant setback in 2026 after the confirmatory Phase III KRYSTAL-10 trial evaluating adagrasib plus cetuximab failed to meet its primary endpoint, creating uncertainty around its accelerated approval in metastatic CRC. Despite this setback, BMS continues to prioritize lung cancer through the ongoing Phase III KRYSTAL-4 and KRYSTAL-7 studies, evaluating adagrasib in combination with pembrolizumab (KEYTRUDA) for first-line treatment of NSCLC. 

Next-generation KRAS Inhibitors to Reshape the Current Therapeutic Landscape

The KRAS inhibitor field has entered a second phase of evolution, shifting from proof-of-concept with first-generation KRAS G12C inhibitors toward next-generation therapies designed to improve efficacy, overcome resistance, expand into earlier treatment settings, and target a broader range of KRAS mutations.

The most significant advancement in 2026 came from Roche’s next-generation KRAS G12C inhibitor divarasib (GDC-6036). In the pivotal Phase III KRAScendo-1 trial, evaluating the drug in 338 patients with previously treated KRAS G12C-mutated advanced or metastatic NSCLC, divarasib demonstrated clinically meaningful and statistically significant improvements in both progression-free survival (PFS) and overall survival compared with the first-generation KRAS inhibitors sotorasib and adagrasib. The study also reported no new safety signals, with treatment-related adverse events remaining manageable and reversible. These results position divarasib as a potential new standard of care for previously treated KRAS G12C-mutated NSCLC and establish Roche as a leading competitor in the next generation of KRAS-targeted therapies.

Moreover, Roche is further expanding divarasib into earlier stages of disease through the ongoing Phase III KRAScendo-2 trial, evaluating a chemotherapy-free combination of divarasib and pembrolizumab versus standard chemo-immunotherapy in first-line KRAS G12C-mutated NSCLC, and KRAScendo-3, assessing adjuvant divarasib following surgery and standard chemo-immunotherapy in patients with resected stage II-IIIB disease.

Beyond divarasib, the development pipeline remains highly competitive. Eli Lilly’s olomorasib (LY3537982) has emerged as one of the leading next-generation KRAS G12C inhibitors and has received US FDA Breakthrough Therapy designation (BTD). The drug is being evaluated in multiple pivotal studies, including in combination with pembrolizumab with or without chemotherapy for first-line advanced NSCLC, in combination with immunotherapy for resectable and unresectable NSCLC, and as both monotherapy and combination therapy across a range of advanced solid tumors. Recent clinical data presented at ASCO 2026 demonstrated encouraging efficacy, with objective response rates (ORRs) ranging from 55.6% to 76.9% and disease control rates (DCRs) of 87.0%–100% across first-line NSCLC cohorts, while maintaining a manageable safety profile. 

Also advancing rapidly is Merck’s calderasib, which is in late-stage development for both NSCLC and CRC. Calderasib monotherapy demonstrated an ORR of 27% and a DCR of 71% in previously treated NSCLC, while its combination with pembrolizumab markedly improved efficacy, achieving an ORR of 72% and a DCR of 95%, with ORRs reaching 87% in patients with PD-L1 tumor proportion scores (TPS) ≥50%. 

Jacobio’s glecirasib is advancing through multiple mid- to late-stage clinical trials in China for KRAS G12C-mutated NSCLC, CRC, and other advanced solid tumors, while InventisBio’s garsorasib (D-1553) is also progressing through late-stage clinical development in China across NSCLC and other KRAS G12C-positive malignancies. 

D3 Bio’s elisrasib (D3S-001), which recently received FDA BTD, is another promising next-generation KRAS G12C inhibitor with an expanding Phase II program spanning second-line NSCLC, metastatic CRC, pancreatic cancer, first-line NSCLC in combination with immune checkpoint inhibitors, and CRC in combination with cetuximab. In an ongoing Phase I/II study, first-line elisrasib monotherapy achieved an ORR of 78.0% and a DCR of 95.1%, with a median PFS of 12.4 months and a favorable safety profile. When combined with pembrolizumab, efficacy improved further, delivering an ORR of 81.3% and a DCR of 97.9%, while median PFS and OS were not yet reached, highlighting its potential as a competitive first-line treatment option for KRAS G12C-mutated NSCLC. 

While the G12C variant remains the most clinically advanced target, the next wave of innovation is rapidly expanding towards KRAS G12D, G12V, G12R, and pan-KRAS inhibitors, which have the potential to treat substantially larger patient populations across pancreatic, colorectal, and lung cancers. Revolution Medicines has emerged as a leader in this space with one of the industry’s most comprehensive RAS-targeted pipelines. Its multi-selective RAS(ON) inhibitor, daraxonrasib (RMC-6236), is the most advanced non-G12C candidate, progressing through registrational studies in metastatic and adjuvant pancreatic ductal adenocarcinoma (PDAC), while also being evaluated in metastatic NSCLC and combination regimens for advanced solid tumors. 

Complementing this program, the KRAS G12D-selective inhibitor zoldonrasib (RMC-9805) is advancing in first-line metastatic PDAC and NSCLC, with Phase III initiation planned in PDAC. Revolution Medicines is further broadening its portfolio with elironrasib (RMC-6291) targeting KRAS G12C and RMC-5127 targeting KRAS G12V, reinforcing the industry’s shift toward mutation-specific and pan-RAS therapeutic strategies that extend well beyond the first generation of KRAS G12C inhibitors. Additionally, Eli Lilly’s LY3962673, a selective KRAS G12D inhibitor, is in early clinical development for KRAS G12D-mutant solid tumors, further reinforcing the industry’s shift beyond KRAS G12C toward broader mutation-specific therapies.

Beyond mutation-specific inhibitors, Cardiff Oncology’s onvansertib offers a mutation-agnostic strategy for KRAS-mutant mCRC. As a first-in-class PLK1 inhibitor, it targets downstream RAS signaling and is being evaluated in combination with standard-of-care chemotherapy and bevacizumab, with the potential to benefit a broader KRAS-mutant patient population beyond the relatively small KRAS G12C subset. 

In parallel, combination strategies utilizing EGFR, SHP2, SOS1, and MEK inhibitors, alongside immune checkpoint inhibitors, have become central to clinical development. These multidimensional approaches aim to block intrinsic and acquired compensatory signaling networks, delay resistance to KRAS monotherapies, and improve the durability of responses across multiple solid tumors 

Pipeline Setbacks Reshaping the KRAS Therapeutic Landscape 

While the KRAS therapeutic landscape continues to expand with next-generation and mutation-specific inhibitors, recent pipeline discontinuations indicate the scientific and commercial challenges of developing KRAS-targeted therapies. As the field becomes increasingly competitive, companies are prioritizing differentiated assets with the greatest potential to demonstrate meaningful clinical benefit over first-generation KRAS inhibitors. 

One of the most notable setbacks came in March 2025, when Bristol Myers Squibb discontinued development of MRTX1133, the selective KRAS G12D inhibitor acquired through its USD 4.8 billion acquisition of Mirati Therapeutics. MRTX1133 had been widely regarded as one of the leading KRAS G12D candidates, particularly for pancreatic and colorectal cancers, but its Phase I/II study was terminated following completion of Phase I. According to the company, the decision was not driven by safety concerns but reflected an unfavorable pharmacokinetic profile that was considered highly variable and suboptimal.

Similarly, Novartis discontinued development of its investigational KRAS G12C inhibitor, opnurasib (JDQ443), following a strategic portfolio review. The decision resulted in the termination of all ongoing studies, including the pivotal Phase III KontRASt-02 trial in previously treated KRAS G12C-mutated NSCLC and the STRIDER study evaluating intracranial activity in patients with brain metastases. Importantly, Novartis stated that the decision was not related to efficacy or safety concerns, but rather reflected the increasingly crowded KRAS G12C landscape, where established therapies such as sotorasib and adagrasib, together with next-generation candidates including divarasib, olomorasib, calderasib, and elisrasib, have substantially intensified competition. Earlier Phase Ib/II KontRASt-01 results had demonstrated encouraging activity, with an objective response rate of 57% and a favorable safety profile, indicating that commercial positioning, rather than clinical performance, ultimately drove the program’s discontinuation.

These discontinuations highlight the changing dynamics of KRAS drug development, where success increasingly depends not only on demonstrating clinical efficacy but also on offering clear differentiation through superior efficacy, improved CNS activity, enhanced durability of response, broader mutation coverage, or more effective combination strategies. As a result, the industry’s focus is steadily shifting toward next-generation KRAS inhibitors and mutation-specific or pan-KRAS approaches capable of addressing larger patient populations and overcoming resistance mechanisms. 

Future Outlook of the KRAS Inhibitors Market 

The treatment landscape for KRAS-mutant cancers has rapidly evolved, with several promising advancements in recent years. The KRAS inhibitor market is expected to grow significantly over the coming years, driven by the increasing incidence of cancer and growing demand for precision oncology. Continued research and late-stage clinical development have broadened the therapeutic landscape beyond first-generation KRAS G12C inhibitors to include next-generation mutation-specific and pan-KRAS approaches.

According to DelveInsight’s analysis, the market size for KRAS inhibitors reached over USD 500 million in 2025 across the 7MM and is expected to witness robust growth through the forecast period, supported by increasing adoption of approved therapies and the anticipated launch of multiple late-stage pipeline candidates. As per the estimates, the US is expected to remain the largest market, accounting for the majority of market share across the seven major markets, driven by early adoption of targeted therapies, favorable reimbursement, and a high prevalence of KRAS-mutated cancers.

NSCLC is anticipated to remain the largest market for KRAS-targeted therapies, supported by the continued uptake of sotorasib (LUMAKRAS) and adagrasib (KRAZATI) and the emergence of next-generation KRAS G12C inhibitors such as divarasib, olomorasib, calderasib, elisrasib, glecirasib, and garsorasib, which are expected to further reshape the competitive landscape. The focus is also expanding beyond KRAS G12C toward KRAS G12D, G12V, G12R, and pan-KRAS inhibitors, broadening the addressable patient population across multiple tumor types.

Following NSCLC, colorectal cancer continues to demonstrate strong pipeline activity, with companies including Roche, Eli Lilly, Merck, Jacobio, InventisBio, D3 Bio, and Revolution Medicines advancing both mutation-specific and combination-based KRAS-targeted therapies. In parallel, Cardiff Oncology’s onvansertib continues to be evaluated as a mutation-agnostic approach for KRAS-mutant colorectal cancer. Although pancreatic cancer carries one of the highest frequencies of KRAS mutations, the treatment landscape remains comparatively less mature. However, increasing investment in KRAS G12D-targeted therapies and pan-KRAS inhibitors, particularly by Revolution Medicines and Eli Lilly, is expected to accelerate innovation and expand therapeutic opportunities in pancreatic cancer over the coming years.

Conclusion: A Glimpse into the Future

The KRAS therapeutic landscape has entered a new era, evolving from the first successful KRAS G12C inhibitors to a highly competitive pipeline of next-generation and mutation-specific therapies. Current innovation is focused on improving efficacy, overcoming resistance, and extending targeted treatment beyond G12C to address a broader spectrum of KRAS mutations. 

While the field continues to witness both significant clinical breakthroughs and strategic pipeline discontinuations, sustained investment and scientific innovation are expected to fuel its continued evolution. As more differentiated therapies and rational combination strategies move closer to clinical practice, KRAS-targeted treatments are poised to transform the management of KRAS-mutant cancers and further improve patient outcomes.

Frequently Asked Questions